Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population
- PMID: 30697776
- PMCID: PMC6712383
- DOI: 10.1002/clc.23160
Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population
Abstract
Background: Survivors of myocardial infarction (MI) or ischemic stroke (IS) are at high risk for subsequent cardiovascular events.
Hypothesis: Older patients with prior MI or IS are at risk for recurrent cardiovascular events, and comorbidities such as diabetes may increase this risk.
Methods: Two cohorts were studied in a retrospective Medicare 20% random sample-a 2008 cohort with up to 6 years of follow-up (MI, N = 26 460; IS, N = 17 566) and a 2012 cohort with 1 year of follow-up (MI, N = 26 548; IS, N = 17 728).
Results: In older patients who survived an event of MI or IS (2012 cohort), 7.2% had a recurrent MI and 6.7% had a recurrent IS in the first year; 32% died. Accounting for multiple recurrent events (2012 cohort), the event rates per 100 patient-years were 11.6 and 10.2 for the MI and IS cohorts, respectively. Cumulative incidence of recurrence (2008 cohort) increased from 7.7% at 1 year to 14.3% at 6 years for recurrent MI and from 6.7% at 1 year to 13.4% at 6 years for recurrent IS. Comorbid diabetes (2012 cohort) was significantly associated (adjusted risk ratio) with MI recurrence (1.44) and risk of coronary revascularization (1.23) in the MI cohort and with IS recurrence (1.26) in the IS cohort.
Conclusion: In this older population with prior MI or IS, high rates of recurrent cardiovascular events and multiple recurrent events were observed. These findings highlight the need for aggressive intervention for secondary prevention and management of comorbidities in high-risk patients, particularly those with diabetes.
Keywords: Medicare; aging and the cardiovascular system; atherosclerotic cardiovascular disease; diabetes; recurrent event.
© 2019 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
Conflict of interest statement
All authors from the Chronic Disease Research Group, which is a program of the Hennepin Healthcare Research Institute, had full access to all study data and take responsibility for the integrity of data and the accuracy of data analysis. Drs Li, Peng, Guo, and Herzog, and Ms Wang are employees of the Chronic Disease Research Group, which is under contract with and has received funding from Amgen Inc. to conduct this research. Drs Qian, Xiang, and Lopez are employees and stockholders of Amgen Inc. Ms Wade reports consulting fees from Amgen Inc. Dr Herzog reports research grants from Amgen Inc. and ZOLL; consulting fees from AbbVie, FibroGen, Relypsa, OxThera, Sanifit, and ZS Pharma; royalties from UpToDate; stock at Merck; and employment at Hennepin Health System. Dr Handelsman reports research grants and consultant and speaker honoraria from Aegerion, Amarin, Amgen, AstraZeneca, Bristol‐Myers Squibb, Boehringer Ingelheim, Boehringer Ingelheim‐Lilly, Gan & Lee, Gilead, Grifols, Hanmi, Intarcia, Janssen, Lexicon, Lilly, Merck, Mylan, Merck‐Pfizer, Novo Nordisk, Regeneron, and Sanofi.
Figures


Similar articles
-
Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome.Am Heart J. 2018 Jul;201:25-32. doi: 10.1016/j.ahj.2018.03.013. Epub 2018 Mar 28. Am Heart J. 2018. PMID: 29910052 Clinical Trial.
-
Effect of prompt revascularization on outcomes in diabetic patients with stable ischemic heart disease and previous myocardial infarction in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.Coron Artery Dis. 2017 Jun;28(4):301-306. doi: 10.1097/MCA.0000000000000492. Coron Artery Dis. 2017. PMID: 28346285 Clinical Trial.
-
Cardiovascular outcomes among elderly patients with heart failure and coronary artery disease and without atrial fibrillation: a retrospective cohort study.BMC Cardiovasc Disord. 2019 Jan 15;19(1):19. doi: 10.1186/s12872-018-0991-1. BMC Cardiovasc Disord. 2019. PMID: 30646855 Free PMC article.
-
Long-Term Risk of Myocardial Infarction Compared to Recurrent Stroke After Transient Ischemic Attack and Ischemic Stroke: Systematic Review and Meta-Analysis.J Am Heart Assoc. 2018 Jan 18;7(2):e007267. doi: 10.1161/JAHA.117.007267. J Am Heart Assoc. 2018. PMID: 29348322 Free PMC article.
-
The incidence of stroke after myocardial infarction: a meta-analysis.Am J Med. 2006 Apr;119(4):354.e1-9. doi: 10.1016/j.amjmed.2005.10.058. Am J Med. 2006. PMID: 16564779 Review.
Cited by
-
Impact of the Pandemic on NonInfected Cardiometabolic Patients: A Survey in Countries of Latin America-Rationale and Design of the CorCOVID LATAM Study.CJC Open. 2020 Nov;2(6):671-677. doi: 10.1016/j.cjco.2020.08.007. Epub 2020 Aug 28. CJC Open. 2020. PMID: 32904407 Free PMC article.
-
Trends in 1-Year Recurrent Ischemic Stroke in the US Medicare Fee-for-Service Population.Stroke. 2022 Nov;53(11):3338-3347. doi: 10.1161/STROKEAHA.122.039438. Epub 2022 Oct 10. Stroke. 2022. PMID: 36214126 Free PMC article.
-
Health outcomes after myocardial infarction: A population study of 56 million people in England.PLoS Med. 2024 Feb 15;21(2):e1004343. doi: 10.1371/journal.pmed.1004343. eCollection 2024 Feb. PLoS Med. 2024. PMID: 38358949 Free PMC article.
-
Long-Term Morbidity and Mortality after First and Recurrent Cardiovascular Events in the ARTPER Cohort.J Clin Med. 2020 Dec 16;9(12):4064. doi: 10.3390/jcm9124064. J Clin Med. 2020. PMID: 33339366 Free PMC article.
-
Mechanistic Insights of Polyphenolic Compounds from Rosemary Bound to Their Protein Targets Obtained by Molecular Dynamics Simulations and Free-Energy Calculations.Foods. 2023 Jan 14;12(2):408. doi: 10.3390/foods12020408. Foods. 2023. PMID: 36673500 Free PMC article.
References
-
- American Heart Association . Cardiovascular disease: a costly burden for America, projections through 2035 (2017). https://healthmetrics.heart.org/cardiovascular-disease-a-costly-burden/. Accessed November 17, 2017.
-
- Murphy SA, Pedersen TR, Gaciong ZA, et al. Reduction in total cardiovascular events with the PCSK9 inhibitor evolocumab in patients with cardiovascular disease in the FOURIER trial. Anaheim, CA: American Heart Association Scientific Sessions; 2017.
-
- Smolina K, Wright FL, Rayner M, Goldacre MJ. Long‐term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes. 2012;5:532‐540. - PubMed
-
- Feng W, Hendry RM, Adams RJ. Risk of recurrent stroke, myocardial infarction, or death in hospitalized stroke patients. Neurology. 2010;74:588‐593. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical